Financial Daily from THE HINDU group of publications
Tuesday, Sep 20, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - New Projects


Natco Pharma to invest Rs 50 cr in expansion

C.R. Sukumar

Hyderabad , Sept. 19

HAVING successfully raised $13.5 million in the global market through foreign currency convertible bonds (FCCBs) recently, Natco Pharma Ltd (NPL) has chalked out expansion and modernisation programme with investments of over Rs 50 crore.

The capital expenditure plans include setting up of a Rs 10-crore finished dosage formulations facility at Dehradun in Uttaranchal to avail itself the benefits of excise duty and income-tax exemptions.

The company is also looking at acquisitions and various other options including trading in non-pharmaceutical products to boost its profitability.

"The company is serious on inorganic growth and is looking around for possible business opportunities. The avenues being looked at are acquisition of brands/marketing companies/facilities abroad," the NPL Director (Finance), Mr P. Bhasakara Narayana, told Business Line.

The proceeds of the FCCB issue are being used to finance the capital expenditure requirements, he said.

The company plans to utilise the Dehradun facility for manufacture of formulation products for sale in India. The plant is expected to go into operation before the fiscal-end. The company proposes to use the Kothur facility exclusively for supplies to the US and Europe.

Natco also proposes to set up a dedicated cytotoxic oncology block for the manufacture of active pharmaceutical ingredients (APIs) at its Mekaguda facility. "The new block will cost around Rs 18 crore and should be operational by April 2006," he said.

The company also plans to set up another production block dedicated for high value, low volume speciality peptide APIs. This is expected to be operational by year-end.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Tata Safari Dicor

Stories in this Section
BPL to retain alkaline battery business


Ranbaxy gets USFDA nod for overactive bladder drug
L&T wins ONGC rig restoration project
Danlaw Tech pref offer
If RIL backtracks on pact with NTPC, Govt may review KG Basin pact
Eveready acquires BPL battery biz
Deal worth Rs 67 cr; market share to go up to 56 pc

Mercedes steps on biodiesel
Natco Pharma to invest Rs 50 cr in expansion
Wage pact in Tata Steel
Beeyu forms joint venture with Fern Tea for Sri Lanka foray
Novo Nordisk, Aurigene in drug discovery pact
`Indian firms must compete with MNCs in global market'
The growing interest
Exit scheme for defunct cos evokes good response
More firms make use of the scheme's extension till August

Tata Tea chief hints at change in business profile
UB charts Rs 100-cr expansion plan — Announces 15 pc interim dividend


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line